Seven Solutions for Neuroprotection in ...
Type de document :
Article dans une revue scientifique: Article de synthèse/Review paper
DOI :
PMID :
URL permanente :
Titre :
Seven Solutions for Neuroprotection in Parkinson's Disease
Auteur(s) :
DEVOS, DAVID [Auteur]
Lille Neurosciences & Cognition (LilNCog) - U 1172
Hirsch, Etienne [Auteur]
Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute [ICM]
Wyse, Richard [Auteur]
Lille Neurosciences & Cognition (LilNCog) - U 1172
Hirsch, Etienne [Auteur]
Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute [ICM]
Wyse, Richard [Auteur]
Titre de la revue :
Movement disorders . official journal of the Movement Disorder Society
Nom court de la revue :
Mov Disord
Numéro :
36
Pagination :
306-316
Éditeur :
Wiley
Date de publication :
2020-11-13
ISSN :
1531-8257
Mot(s)-clé(s) :
preclinical studies
drug development
s disease
clinical trial
Parkinson&apos
modifying effect
disease‐
neuroprotection
drug development
s disease
clinical trial
Parkinson&apos
modifying effect
disease‐
neuroprotection
Discipline(s) HAL :
Sciences du Vivant [q-bio]/Neurosciences [q-bio.NC]/Neurobiologie
Résumé en anglais : [en]
Parkinson's disease (PD) is a neurodegenerative disorder characterized by loss of dopaminergic neurons in the substantia nigra and accumulation of iron and alpha-synuclein; it follows a characteristic pattern throughout ...
Lire la suite >Parkinson's disease (PD) is a neurodegenerative disorder characterized by loss of dopaminergic neurons in the substantia nigra and accumulation of iron and alpha-synuclein; it follows a characteristic pattern throughout the nervous system. Despite decades of successful preclinical neuroprotective studies, no drug has then shown efficacy in clinical trials. Considering this dilemma, we have reviewed and organized solutions of varying importance that can be exclusive or additive, and we outline approaches to help generate successful development of neuroprotective drugs for PD: (1) select patients in which the targeted mechanism is involved in the pathological process associated with the monitoring of target engagement, (2) combine treatments that target multiple pathways, (3) establish earliest interventions and develop better prodromal biomarkers, (4) adopt rigorous methodology and specific disease-relevant designs for disease-modifying clinical trials, (5) customize drug with better brain biodistribution, (6) prioritize repurposed drugs as a first line approach, and (7) adapt preclinical models to the targeted mechanisms with translational biomarkers to increase their predictive value. © 2020 International Parkinson and Movement Disorder SocietyLire moins >
Lire la suite >Parkinson's disease (PD) is a neurodegenerative disorder characterized by loss of dopaminergic neurons in the substantia nigra and accumulation of iron and alpha-synuclein; it follows a characteristic pattern throughout the nervous system. Despite decades of successful preclinical neuroprotective studies, no drug has then shown efficacy in clinical trials. Considering this dilemma, we have reviewed and organized solutions of varying importance that can be exclusive or additive, and we outline approaches to help generate successful development of neuroprotective drugs for PD: (1) select patients in which the targeted mechanism is involved in the pathological process associated with the monitoring of target engagement, (2) combine treatments that target multiple pathways, (3) establish earliest interventions and develop better prodromal biomarkers, (4) adopt rigorous methodology and specific disease-relevant designs for disease-modifying clinical trials, (5) customize drug with better brain biodistribution, (6) prioritize repurposed drugs as a first line approach, and (7) adapt preclinical models to the targeted mechanisms with translational biomarkers to increase their predictive value. © 2020 International Parkinson and Movement Disorder SocietyLire moins >
Langue :
Anglais
Audience :
Internationale
Vulgarisation :
Non
Établissement(s) :
Université de Lille
Inserm
CHU Lille
Inserm
CHU Lille
Collections :
Équipe(s) de recherche :
Troubles cognitifs dégénératifs et vasculaires
Date de dépôt :
2021-06-16T06:22:03Z
Fichiers
- MDS-20-1261.R1_Proof_hi.pdf
- Version finale acceptée pour publication (postprint)
- Accès libre
- Accéder au document